A UK biotechnology startup is entering the crowded obesity drug market, armed with $411 million and a promising ...
Americans elect their leaders on the premise that those individuals will be capable of making the right decisions on difficult, as well as easy, issues. An issue on which members of Congress might ...
Eli Lilly’s obesity drug Zepbound is now covered by Medicare for sleep apnea treatment, expanding access to the costly ...
"Coverage for these weight-loss drugs has significant cost implications for employers, as a previous KFF analysis estimated ...
Eli Lilly’s popular anti-obesity drug Zepbound could get a sales boost after the U.S. Medicare program decided to pay for its use to treat sleep apnea. The Centers f ...
Eli Lilly's popular obesity drug Zepbound can now be covered by government-backed Medicare drug plans, CNBC reported on ...
Eli Lilly's (NYSE:LLY) weight-loss drug Zepbound is now reportedly covered by Medicare for the treatment of obstructive sleep ...
It opens the door for broader coverage and access to Zepbound, which is not currently covered by Medicare and many other ...
The National Taxpayer Advocate has urged Congress to preserve IRS funding for taxpayer service and technology amid Republican scrutiny.
Eli Lilly's Tirzepatide Outshines Novo Nordisk's Semaglutide, Yet Brand Recognition Remains Strong for Novo's Products ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback